Indeed, it has been suggested that some of the clinical efficacy of lenalidomide in B-CLL derives from its ability to increase the expression of NKp30 on NK cells and increase tumor cell lysis [44]. This evidence concerns the gene NCR3 and B-cell chronic lymphocytic leukemia.